Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxObnNXQXlaUjlNVUtBTGYtZ2gxcHJjdnBfV2hKLUYxSG5YQUhrTWJhd1hxMkJ6cE5scGpreXBRTGZWNjNmSU1EZXgtMHR1TDJRTXB4S1hZZ09COEZtLURtVFlFSDVwaUxWSW1MMm9lT0t0UmRCMFdsd0NXUXhQeHExNk1SNHB1MHBKQURYc0JJTXJLUEx5VDFhcDY5aFNfSTB2ZkgycEtB?oc=5" target="_blank">Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
Novig Sign Up Bonus: ROTOWIRE Gets $50 in Trade Credits
Boise State gets big health boost, but injury concerns remain vs. Fresno State
NEvsSEA Starting XI: Dejan Joveljić and Yeimar return to starting lineup, Sebastian Gomez gets the nod
Pedro Pascal in ‘Behemoth!’: The Oscar-Worthy Role That He (and Latinos) Have Been Waiting For
Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxPZ0lwMlgyb0prZndsRVk5S3dqUGstdjdEaVYtbHhiWFRaS0IwQXlpbjNNd3p4ZkdjR0FibnRqeXZZQWtINS1ubUVZeVl2dTl0aW9zWFJyd2Vka2hia3U3aGJiV3BVblNSWHVuWjVNTGdyM3NGSzl0RVBOSm83V0lfdkdQNml1blZjSUVSTUlWQ04?oc=5" target="_blank">Trispecifics: A New Strategy to Prevent Antigen Escape</a>&nbsp;&nbsp;<font color="#6f6f6f">Targeted Oncology</font>
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNbmtiVHZocGdMWGo0TXZVUEEwNFNpQWw0NzdiWXpvLVpmbzJ2SHNMU0gwQkNTZ05KdDZKekZGdkRic2NYU1RYQTN6MUUtTFVWQ3B6ZEpOT2VqeFFBOElUZHltdTlkSkY5UC1OMGNCcER5MDJjWlFDTEg5dEtYVGx1djdhelJVUlVvZVlHdG01Z2FnUQ?oc=5" target="_blank">Immune cell engagers in lung cancer</a>&nbsp;&nbsp;<font color="#6f6f6f">Frontiers</font>
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPMFRwU0gtdVlYOHRyeFdRWU4zMmxiWC1ueGNaWTNFemRjUmtXUFpWcVV1ZUQ3LXlWc0JjeWVET3lsRk9aaWM2Z3VEV1FHd1d0czh2dG1oa3VNOWFzV2N1c2k1czFnX24wRnUyTTBxLUdITHdwUndDNGxtazJ0azFDS21tNmJzVXFZbWcwWFVIZGJBSk85SVFyRll6TjQyRnlfeTJqZGpsaVpScTVDRlJKd3d4Um41NlV5NFlj?oc=5" target="_blank">New T-cell engager therapy shows effectiveness in advanced solid tumors</a>&nbsp;&nbsp;<font color="#6f6f6f">News-Medical</font>
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQYWtsck1Nc0tkUnNkaHpPU1VBMzE5Ym1LM3g1eUtuTU42dTUwTjU4dFZyY3RmTXQ3WmVGSEVhdjFaUzRSLVRIMklSWHJiRGN6U1FvcDE0U2ZpT0NEMG5WVEVnck1YLXJ4VEVPd3lmSmZSRHFjdUN5c0xyaWRQZTdnZTg2M0JEQnRObnZSblowcnBzOW1xWFd1WVYwU1UzWnBF?oc=5" target="_blank">Engineering the next generation of T-cell engagers</a>&nbsp;&nbsp;<font color="#6f6f6f">Drug Target Review</font>
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOUmt4TjI4cGt1MFVDd0hCWmxHOUZfaDJnRkVWMWFTOGFfZGpsRDhqZ1pVOFlKOFMtSjYzb1dFLXljdnc2OTdiVG5rR0paV3E2OGczLU1rYXFFcmN4cVNrRVJkcEFLNXAxdWxlaVc4YWQycXdPc0xkSXMxeW1od2lUOTdyOTQ0dWdlT1VkZ2ktSlk4Zw?oc=5" target="_blank">Cytospire hauls in $83M for a new type of T cell engager</a>&nbsp;&nbsp;<font color="#6f6f6f">BioPharma Dive</font>
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQSjZnX3cxTjM3bFdnNHp6RU5zRkRab09XM010UGV0eDRJcTUzbGs1MmtrdV9IX2lsN19ZOXF4Qmp4VDhZVGx6RGFrMXV6V1k2aXlGaUk0ZjJtTTVWNFVlZnhpY1ExMjR1bVV4YXhnRU9hWnBRWWlvWkVfNU9jbkdHaTQxSTFZNEpVT0ZmanFBYU1hM0hCRGJnWl9kOWQyb0NFbGd5eGgtU0g?oc=5" target="_blank">T cell engagers emerge as a compelling therapeutic modality</a>&nbsp;&nbsp;<font color="#6f6f6f">Rockefeller University Press</font>
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxPQXA5TVg1cFRDRXMwdzIyUFZYWUEwRFpNUlRuUUF1Yy1zNklyQXNyNlB1cHU1UEFGS3pIZHNtaDdvaHFoYWduX2ZDdXNwTFdITzdrMWFBYWFRUHNmZ3BXVllCWFAzY0JUQjBZWlRrTDdLbnUwSGlNeGhTdHF2YUFRMldGWHFNSGNh?oc=5" target="_blank">UK's Cytospire draws in $83m for new T-cell engager platform</a>&nbsp;&nbsp;<font color="#6f6f6f">pharmaphorum</font>
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOUkI3ejBuRXJLQ3JENXdLdHFYSVMwMjRhMWh2RDBuVUJQem5xRDlwMjZqbHBoQkRmajViTG8yZDhCbHFBQ0NaRVJ4XzN1VlU2T0FIcHptRmZ3TFM0Qm5JNEpSaU9ZUjJvMFV6WHdDUmFHNlVuUnZMYUxzNWxFYkpTMzM0WG54aXpDdkRLVTg0UGlJenVuT1J4QlFLbmg?oc=5" target="_blank">Next-Generation Precision Medicine Platforms Come for Cancer</a>&nbsp;&nbsp;<font color="#6f6f6f">The Scientist</font>
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQYU5NYkdFaUJ6QnlfOEE4elI1R1dyNW1FMzRYb2J5YktJUkRhaEZvX1cwcnBqaUhURVlPVlpTZ19OZ2VuTnBaMGtsTFhtWHQxbGJKYWppLW5hbElIeTFZVmFzalRhc1JmS05EVTlCX2JxMVJsc3lDdGExUXF4dFdNUE5sWWpRRTJPN01Cc2paZ3U5MlVvNm9Zd3FyRF9OSmtnNEE?oc=5" target="_blank">What New Treatments Are Improving Survival in Small Cell Lung Cancer?</a>&nbsp;&nbsp;<font color="#6f6f6f">Cure Today</font>
<a href="https://news.google.com/rss/articles/CBMiuAJBVV95cUxQcG1LSHREWWRGQU9lZGxMTWF6dkMwNkNTcGthYUVpREI1dWIxU0wyUk9pU3hhX0wwOWxfcnVkVERNWnE4Sm9jVVVpNnNPTHF5VWx4TUp0VzVMVzI5clBJVGYydnNzVW9vcExyNkVhdlZjM0NfYzZveWU5TnlOUm5MVUQtY2NLdHpfb0dPb1hmUXNZZlJfQ01IVDBSdzR3Ql9zVEQ0MkY5eXg0bThaWUFsYWRnYWJQclh6WndaRTdUX2s0Z2J1VVFOZ2ZqbmxYM29CbzlzbWlpTnBoV05aaTZxTHpmRlVKRjB3NGZMV3hqWGctZm9aZ3A3WE44YzBIX0o1dkM0YUVzd0p0YjhoMEJIUzFWV3ZzZjJjVWVPaG1ScmxSaVd3S3ZvdmdaY3pQSHM3VWlDLVlRYkM?oc=5" target="_blank">Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases</a>&nbsp;&nbsp;<font color="#6f6f6f">GlobeNewswire</font>
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOMGgxRUlQSWVZR2pENG5COXJ0Z3dQamdDUXNkQlY4WXREckN2anZvQnNMNFN3LTJGdFNtb0lRUGVLOHJfdmxEaDJXOFA2Vk1RX3M0YTZ5bGNNLVZIZGFYOHF0VTlzelhPcjMyNlJGQW5Yc1N6a2hYMTF0TnJfYkpTcy0tdUxyakdheUZrRmRxX3R2UktGWWpnbl9IMThHcm5BcG4zRV9hR0EyRWJUZUE?oc=5" target="_blank">Emerging Strategies in Prostate Cancer: Molecular Glues and T-Cell Engagers</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMijwJBVV95cUxPSG1pdXRUWmJxSTNqMW8zS2hOM3pOMXpDR2xqVkRtZ0ljeEpfekNfbTlwYURkVjgtNnhFeVBpYmZGWnlrTml1RG5mQW5oWWFrbEpSeGJNUGhQSEx6V0g4RFR5ckxlWlQ0WWlSQkd1T1hjMGFaNlRMU2V1OElESDk2Vnl2bk1zTldhTU1nZW0zRFlCR0xMQ1UyOVZ2RWtnM2xCMmVCTlhvcEVneUF6azdjRWkyQmdkTl81cXYyaXRScDlOSElLNmpQWjQxQ0hmb2NTMm0zVDBfMjlJb1R5dlJWbThlaG81SWxpbXc0N0U4dUdDbUJIRXlZRGJMV2xQaFd5YU9iRjRHUG5rOGE1UG9z?oc=5" target="_blank">NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors</a>&nbsp;&nbsp;<font color="#6f6f6f">Business Wire</font>
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNQ2hDWnkybkVwbVFDbUhQMzU3YW9WSmpCdkMwN3VPeDNVOHQwTVZDVm1OcTBBN3JYdXBLeE93RFgyenJPa1JFM1pONlgzV2RpeTNnOFYwS25wbGRyWVp5VEh5Uk04RUphUWtYVmJ1OVBZUEh5Wm9HaFZoakstUlZHNlphSzh2SW9URjdMSEMzWUpyLURvZFlfWFltTzczcVRRODJ6TlctakFkeE0?oc=5" target="_blank">Gilead's $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos</a>&nbsp;&nbsp;<font color="#6f6f6f">Fierce Biotech</font>
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQdU5ROTdrX25ybWhCSEJEd05DeVR5X2d1dDhndVVaZzVDdmRPbzBmQ0lJZVIybTdwSVZqU2xlajFiTDhFTXJqaHNyTnVRWlh5bllvUnotNVROVnZESjluUEJhVjhVOXMxRE1PMHJZN0JwQkswSlppX2Q4dEpISjRjRWtiTkJ6QWxSN0wtbkF5TjllUQ?oc=5" target="_blank">Smart control of CAR-T cells: emerging strategies for safer and more effective cancer immunotherapy</a>&nbsp;&nbsp;<font color="#6f6f6f">Frontiers</font>
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOYkRNZE11NGFRcVFUVWRWcGx6WjFYVHpwRkZiQWFyNTVrcExZMWR3OVEtTFdBUUxpZHEycVFCMThUbndvN2Y3RTNRZEdONHhFMmZ4ZjFNdlY0bUJyVEVGdk9feV9pM2dGWG9jeDhYVUZjOW1xNHQyelkxazNfQ2FQSVdUOHZOT2MtanJicG50WGJQQ09VSVVjYkZLLWk?oc=5" target="_blank">AbCellera, Vertex partner on next-gen T-cell engagers</a>&nbsp;&nbsp;<font color="#6f6f6f">BioPharma Dive</font>
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQcXk2MTRFdnVwRUxBSkxrTkpaX2VhSUgzRFRlV3YyZkgxS2VrUkJGWXdTOFVGYkdISFhqNW9oZFBtSlV4WEJ2TE5NNGpBRTFUdW1Od21IY0J6cEpSbVZ0Wnl6VVQ5dmVtYllQbU5KTzFBbUZ2eC1yOGZBNko4SkFteGpFWmhzUzV0ZURIZTZhU1I?oc=5" target="_blank">Future Directions and Emerging Therapeutic Innovations</a>&nbsp;&nbsp;<font color="#6f6f6f">Targeted Oncology</font>
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQWXVGRXNpN0x4dEZSSkJUeUZ5cEhBSEsyRHdUTktlWGpSUFNRQVE4V25tckprbEVaR2xmM2drWDBIbDN0SFpxZjZKTWRYWThDdE5hWHlfbmxkNEpEeHlJbzNNZjVfXzZtTmJXRFVkR2gzNDQyX3R2UUpIR1VocUh2bDlLZ2xjWlhUSGdDcWY0MHNyV2JpMURTOEh4ck1TZw?oc=5" target="_blank">How New Therapies Are Changing the Game for Small Cell Lung Cancer</a>&nbsp;&nbsp;<font color="#6f6f6f">Cure Today</font>
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNbUpxNTFqRDRfZ1ZSWkxaNElFaDE4T2FvTVRZNDcxX0tXc2xoZW11LXpZVU1nbWx6QXUybUVXTDVWZ21ubkkyUjVxSy1zWEdpWG1sR2FRTTZwT1hDb0xhWHhSdy1faGZWRFV4UWp4U2RMNldKWU5ORDNRSExfeTZZTVJGaTF6NXVNWHIwR0o5aDFiQQ?oc=5" target="_blank">CAR-T and BiTE: new horizons in the treatment of rheumatic autoimmune diseases</a>&nbsp;&nbsp;<font color="#6f6f6f">Frontiers</font>
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQWC16LUxrcEE4TlFDNi1jek8wOFBwSUYzb3NwNThiTHBBYlpGNVVuRWNGZkJaUWVqNmI4d3JLOUw1RjNRYWk3clBfQjJjWm9Ya0w0NjRySXREMU11bjRQVVNGcDVrU2hvTTNrT0hxdmc2cGdWNE5TcUhQVFBxNXBWLW9TU3lTbTRmTHdfUzc0RXI?oc=5" target="_blank">Crossbow raises $77M for new cancer immunotherapies</a>&nbsp;&nbsp;<font color="#6f6f6f">BioPharma Dive</font>
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQNy15ZUhxdUg2WTVoOUNHcWhRMTNkV2RIZjlTSzZuYTR5aTJEa3hIT0dWXy12M0RmZWkxdHJpUng4M2JmdFpfR3dHNDV4NjdfME55aThsdlVPMm5VSm01NWdBajE1R2NyLW54SUVaVWw0WjZjSzYzR2FUVnlzY0NqYUkyd20tdmdKb0J3bFRTX0poUXhUbXZNVi1vQnp4bEJ4?oc=5" target="_blank">GSK pens $50M LTZ pact to join Big Pharma peers in emerging myeloid cell engager space</a>&nbsp;&nbsp;<font color="#6f6f6f">Fierce Biotech</font>
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOV2JhUGlDeEJrc3pjWTI4ajQtaFhwRllFZl9Oa1otQ2xqdFNHbU81YV9xenpQS3lFQ2M1UUxJNjVHOW5CVGN6dlBXU0dORWFMeTl6WFNkS1cyNDVhR2h3Y0V6S1dLekhIdjEzUjZ0ZnFIcERJYkpxZUszUWY4Zy13a3Q5d3c0ekVfV0VjTzZXWTYybkdSODdV?oc=5" target="_blank">Navigating New Horizons in Neuroendocrine Prostate Cancer</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPMUZvV1NOX3lrTjRNV2UxT3drQWRkTFZDNzhnOXd2a1FQYjVrLTBkaFlROGlZbVZXcXVwYXNWQjZiYThqYnZFVkFuTDdVOENxRWxQd2p2N010X0dpU1RpS0IwSzFlVGZzQlZHTWJlZEtRR0FPTWFNeEE0aGw4R0kxTkl1Ym1tQndUYkxj?oc=5" target="_blank">The Shift to Complex Modalities for Cancer Treatment</a>&nbsp;&nbsp;<font color="#6f6f6f">PharmTech.com</font>
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOeTFEMDA5MW9HdExLbWN4RU5HbmN0eXBMcER1ZlVJbVVQbS1IcWluV1hoNm5HXzQ0N29NdUxCOUUtV2ZoMEpfMnM2QVJmMjVWLVd5QV9ycEQycm4wMS1yYlFVd2s1VkpNLVZKRzRZM3dOZXBWNF9GVnhGaVVHdzJDQUU2bWV6TGtGcjRYY0xHSktwTzhfMEFj?oc=5" target="_blank">UCB inks $2B Candid buyout to join Gilead in autoimmune field</a>&nbsp;&nbsp;<font color="#6f6f6f">Fierce Biotech</font>
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQRERHa1BOeGNUVjVOcXlPMVhJdG90V1ZWSjlwLWVFRkpiUU1jX3dON3hYbVNqZ3VoaG9vaXdLeVNINUxNUnR4aC1nSkVreE1RSzVzZlVMdFRzU1VGUDlVYy03RzZiVS1ibGdRS2xnVUZoT0VTVDhzQlgxb001SnBvWHNXeHlhQjNTVkdvTUxJbWdjVXIwcjNjandXX1NXRnNFa1VPeUhTdzA?oc=5" target="_blank">UCB enters TCE space with $1.1B deal for autoimmune candidate</a>&nbsp;&nbsp;<font color="#6f6f6f">Fierce Biotech</font>
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQRlkxX296RjhMQ1lyQ0U5RmVtdTFfbEx6djBxZWFfUTlrM1JSaHV1clJQRXI2ekRyckhQMERiVjN4WXhXOFhhUUZBX1ZObFZDNzhHMXdrZ1ZqclgxamZUc3lqYV9sNVJjZERxdVFBMnBpTG9IeG1naDJzNXFoRU15Sko2ZHo3UWhiY1RVNnR5M3ROT0RZTm5PeVBNTC1OS2w0WndKUjNWdW1pMjdNVHNz?oc=5" target="_blank">Oblenio Bio Raises $62M to Advance New Therapies for Autoimmune Diseases</a>&nbsp;&nbsp;<font color="#6f6f6f">citybiz</font>
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOeGdmbENQWExRZmpjemtpZGh4WFFyWUc3R0RFS19JY3dQYzFEUzBSa0lmRFI4Q3Q4VThnS3Y2U3A5bjVxaFp6Y256MEJKanJJVTY5WDFwempYU0ZwOTZCWVlJemlRMFRnUWpHdlJPLUlTNXVnSXBUUVlLd25VWWdmZmRBWU1ydklQQmtFV01OTzd0UG55TlRJY1lwenREbUYwdG1PQXJ2eGpPa2Zhc2x5dWV5WllMLWVpZjNYWEtMRmlleHQtY2JVdjBIRU53X01TeE5v?oc=5" target="_blank">Advances With Checkpoint Inhibitors, T-Cell Engagers, and ADCs Converge to Reshape the SCLC Treatment Paradigm</a>&nbsp;&nbsp;<font color="#6f6f6f">OncLive</font>
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQSEl5RUtOX3lDTVdRa1lPOGdKYzUtZlByZ29WZkdTYnBDSEZZczJHaXM0WnJPRnQ4VHF0endhNFRjVG81M1FJQzB6a0VPa3lGX3JwZ3hhcmVSN2dQVm45akZmV1hZN0JTR21NR054Mjg3djc4X25jbjhaNWl4NTVwOUg4M0JLdTNUbE9RckdaMUhyZno5d2NfMWJGWElXQmJkY3c?oc=5" target="_blank">J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio</a>&nbsp;&nbsp;<font color="#6f6f6f">Fierce Biotech</font>
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNLXBISE5GSFVSU0J3LXdlTUpVcmZsb1gtcU1MRFlCSW81UUVRNUMtaWVqVV9ESTJuYXJGYXg4SjZDY0Fsa01waU53bUZkYUJsZUJ5eVFZc3I3bVRQejBJQXIxaVRZWFMyVmx2ZHRyZy1HQnJqa1dVeW1HSzFkV3NzN2ZkeXkyWGZ6WnJtUElyWnRQUm1tS1Zpb1Ryc3dnRnN1NGJNRmdINU1WTnJpcjRQUkk0U1FWMFRYcmR2bkhIMnVnUQ?oc=5" target="_blank">Scientists explore new frontier in autoimmune disease treatment by resetting 'rogue' cells</a>&nbsp;&nbsp;<font color="#6f6f6f">PBS</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE55VVBjV2dfT1ZUbjBaTXpBQjFXZWhnRlJjNzdCR2hLR2owMGJ3cHZHVkdfMGQ1OWhlcXN4SE5FZ2J2SzQ1eXZXVUxnazkyaUIzX3ZZbmpVWXpaNEQzLURR?oc=5" target="_blank">New immune cell engagers for cancer immunotherapy</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>